NAPRT and neoplasm: Any therapeutic strategy aiming to block only one route of NAD+ biosynthesis should therefore be expected to fail in tumor cells in which the enzymatic apparatus of both NAD+ production routes (via NAMPT and via NAPRT) is expressed.